Controlling the type 1 error rate in non-inferiority trials

被引:19
作者
Snapinn, Steven [1 ]
Jiang, Qi [1 ]
机构
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
关键词
assay sensitivity; constancy; fixed-margin approach; power; synthesis method;
D O I
10.1002/sim.3072
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Two different approaches have been proposed for establishing the efficacy of an experimental therapy through a non-inferiority trial: The fixed-margin approach involves first defining a non-inferiority margin and then demonstrating that the experimental therapy is not worse than the control by more than this amount, and the synthesis approach involves combining the data from the non-inferiority trial with the data from historical trials evaluating the effect of the control. In this paper, we introduce a unified approach that has both these approaches as special cases and show how the parameters of this approach can be selected to control the unconditional type I error rate in the presence of departures from the assumptions of assay sensitivity and constancy. It is shown that the fixed-margin approach can be extremely inefficient and that it is always possible to achieve equivalent control of the unconditional type I error rate, with higher power, by using an appropriately chosen synthesis method. Copyright (C) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:371 / 381
页数:11
相关论文
共 22 条
[1]  
CBER/FDA, 1999, SUMM CBER CONS SEL A
[2]  
Chan Ivan S F, 2002, J Biopharm Stat, V12, P457, DOI 10.1081/BIP-120016230
[3]  
*CHMP, 2005, EMEACPMPEWP215899
[4]   Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics [J].
D'Agostino, RB ;
Massaro, JM ;
Sullivan, LM .
STATISTICS IN MEDICINE, 2003, 22 (02) :169-186
[5]   Placebo-controlled trials and active-control trials in the evaluation of new treatments - Part 2: Practical issues and specific cases [J].
Ellenberg, SS ;
Temple, R .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (06) :464-470
[6]  
Hasselblad V, 2001, DRUG INF J, V35, P435, DOI 10.1177/009286150103500212
[7]  
Hauck WW, 1999, DRUG INF J, V33, P109, DOI 10.1177/009286159903300114
[8]  
Holmgren E B, 1999, J Biopharm Stat, V9, P651, DOI 10.1081/BIP-100101201
[9]   Some fundamental issues with non-inferiority testing in active controlled trials [J].
Hung, HMJ ;
Wang, SJ ;
Tsong, YL ;
Lawrence, J ;
O'Neil, RT .
STATISTICS IN MEDICINE, 2003, 22 (02) :213-225
[10]  
*INT C HARM, 2000, E10 ICH